Drug Profile
Research programme: anticancer angiogenesis inhibitors - Bionomics
Alternative Names: BNO69 siRNA therapeutics - Bionomics; BNO69-targeting therapeutics - BionomicsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bionomics
- Class Small interfering RNA; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Australia
- 24 Aug 2010 Preclinical development is ongoing in Australia
- 03 Aug 2004 Preclinical trials in Solid tumours in Australia (unspecified route)